Kairos Pharma Receives FDA Approval of Investigational New Drug (IND) Application for Its Phase 1 Clinical Trial of KROS 201 for the Treatment of Glioblastoma; Announces New Patent for KROS 401

March 14, 2022 Los Angeles Biotechnology Network News Los Angeles Biotech News Comments Off on Kairos Pharma Receives FDA Approval of Investigational New Drug (IND) Application for Its Phase 1 Clinical Trial of KROS 201 for the Treatment of Glioblastoma; Announces New Patent for KROS 401

Phase 1 clinical trial of KROS 201 to begin in 2022 at Cedars Sinai Medical Center New patent covers the method of treating fibrosis and certain forms of cancer, the composition of matter, and administering a therapy using KROS-401 LOS ANGELES, March 14, 2022 /PRNewswire/ — Kairos…